Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
Non-Typhoidal <i>Salmonella enterica</i> Bacteremia Complicated by Native Shoulder Septic Arthritis in a Patient with Sickle Cell Disease Following Foodborne Exposure: A Case Report and Literature Review. [PDF]
Godart GA +7 more
europepmc +1 more source
Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo +7 more
wiley +1 more source
Staphylococcus aureus Pyogenic Spondylodiscitis in a Patient With Rheumatoid Arthritis Receiving Rituximab. [PDF]
El Kacem EM +5 more
europepmc +1 more source
Human Fibroblast–Myeloid Cell Tissue Atlas Across the Lungs, Synovium, Skin, and Heart
Objective The availability of single‐cell RNA sequencing (scRNAseq) data in different tissues and disease states provides an opportunity to compare cellular subsets and identify common and unique cellular activation. In this study, we aimed to characterize shared and tissue‐specific myeloid and stromal phenotypes and to uncover key cellular subtypes ...
Lucy MacDonald +9 more
wiley +1 more source
Disseminated <i>Ureaplasma</i> infection: a case report of a patient with rheumatoid arthritis on rituximab therapy with multiple abscesses and arthritis. [PDF]
Sindelar L +4 more
europepmc +1 more source
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz +13 more
wiley +1 more source
Whipple disease presenting with severe weight loss, seronegative inflammatory arthritis, and culture-negative endocarditis. [PDF]
Khan F, Conradie J, Schell A, Gillrie M.
europepmc +1 more source
IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis
Background Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. Immunoglobulin G (IgG) from LN patients displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay +3 more
wiley +1 more source
Tofacitinib: New drug in the therapeutic armamentarium in ocular inflammation. [PDF]
Babu K, Mooss V.
europepmc +1 more source

